Table 1 Baseline demographics of patients with Parkinson’s disease (PD) and the healthy controls (HC)
PD-RBD(+) (n = 57) | PD-RBD(−) (n = 47) | HC (n = 85) | P value | |
|---|---|---|---|---|
Age, mean (SD) | 66.1 ± 7.1 | 61.9 ± 8.8 | 64.6 ± 8.0 | 0.03 |
Male, n (%) | 36 (63.2%) | 19 (40.4%) | 40 (47.1%) | 0.05 |
BMI (kg/m2), median (IQR) | 24.3 (22.3–26.7) | 24.5 (22.2–26.6) | 23.9 (21.5–25.5) | 0.26 |
Education (years), median (IQR) | 12.0 (9.0–16.0) | 12.0 (12.0–16.0) | 12.0 (12.0–16.0) | 0.33 |
IBS, n (%) | 1 (1.8%) | 1 (2.1%) | 3 (3.5%) | 0.79 |
Constipation, n (%) | 29 (50.9%) | 18 (38.3%) | 11 (12.9%) | < 0.001 |
Disease duration (years), median (IQR) | 2.0 (0.0–7.0) | 2.0 (1.0–4.5) | – | 0.94 |
Hoehn & Yarh stage, median (IQR) | 2.0 (2.0–3.0) | 2.0 (2.0–3.0) | – | 0.59 |
UPDRS Part 3 score, mean (SD) | 33.0 ± 13.0 | 29.9 ± 9.9 | – | 0.28 |
UPDRS total score, mean (SD) | 48.0 ± 19.5 | 43.7 ± 15.3 | – | 0.33 |
Use of levodopa, n (%) | 45 (80.4%) | 40 (85.1%) | – | 0.30 |
Use of dopamine agonist, n (%) | 18 (32.1%) | 23 (48.9%) | – | 0.08 |
Use of COMT inhibitor, n (%) | 2 (3.6%) | 7 (14.9%) | – | 0.09 |
Use of MAO inhibitor, n (%) | 17 (30.4%) | 8 (17.0%) | – | 0.18 |
Use of amantadine, n (%) | 12 (21.4%) | 9 (19.1%) | – | 0.97 |
Levodopa equivalent daily dose | 450.0 (225.0–711.2) | 450.0 (300.0–730.0) | – | 0.96 |